Biosynex specializes in the research, development and manufacturing of fast diagnosis tests on membrane support for health professionals (biologists, clinicians, nurses and midwives). Products are used in the tropical diseases, autoimmune diseases, emergency markers and Infectious diseases fields. The company's activity is organized around 5 areas: - manufacturing of diagnosis tests for own account; - sale of diagnosis tests supplied by other manufacturers of semi-finished products; - research and development services for third party; - sale of licenses; - sale of biological reagents.

Employees

397

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change	Volume
26-07-02	€0.9040	-0.66%	907
26-07-01	€0.9100	+0.89%	4,806
26-06-30	€0.9020	-0.22%	4,861
26-06-29	€0.9040	+1.12%	2,600
26-06-26	€0.8940	0.00%	16,560

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-07-02 EDT			5-day change	1st Jan Change
0.9040 ^EUR	-0.66%		+1.12%	+51.68%

06-11	Triple update for Biosynex
05-25	Paris climbs on hopes of Middle East de-escalation

Market Cap	16.66M 19.07M 15.3M 14.27M 27.05M 1.82B 27.51M 184M 71.4M 890M 71.6M 70.04M 3.07B	P/E 2024	-0.43x	P/E 2025	-0.19x
Enterprise Value	69.85M 79.94M 64.14M 59.82M 113M 7.61B 115M 772M 299M 3.73B 300M 294M 12.86B	EV / Sales 2024	0.71x	EV / Sales 2025	0.68x
Free-Float	40.35%	Yield 2024 *	-	Yield 2025	-

06-11	Triple update for Biosynex
05-25	Paris climbs on hopes of Middle East de-escalation
05-25	Biosynex announces the divestment of its molecular biology business
05-24	An undisclosed buyer signed a binding offer to acquire Entire internal molecular biology business from Biosynex SA for ?4 million.	CI
05-07	Biosynex SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-06	Biosynex SA Auditor Raises 'Going Concern' Doubt	CI
04-21	Thales, Vivendi, Mercialys, GTT... stocks to watch today in Paris
04-21	Biosynex postpones publication of annual accounts
03-24	Abivax, Ekinops, Sanofi... stocks to watch today in Paris
03-24	Observation period extended for Biosynex
02-06	A Biosynex Subsidiary to Receive $1.8 Million Grant
02-06	Aperam, Société Générale, Stellantis: Key Stocks to Watch Today in Paris
01-23	JCDecaux, Sanofi, Sword Group... Stocks to Watch Today in Paris

24-10-23	BIOSYNEX SA: CHEMBIO DIAGNOSTICS INC., A SUBSIDIARY OF BIOSYNEX, RECEIVES A GRANT FOR DEVELOPMENT OF A DPP CONGENITAL SYPHILIS ASSAY	EQ
23-04-27	Biosynex Completes Acquisition of Chembio Diagnostics, Inc.	AQ
23-04-13	Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.	AQ
23-03-15	Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.	AQ
23-01-31	Biosynex and Chembio Diagnostics Announce Definitive Acquisition Agreement	AQ

Biosynex Stock

Stocks

ALBIO

FR0011005933

Medical Equipment, Supplies & Distribution

Valuation: Biosynex

Chart: Biosynex

Latest news : Biosynex

Press Releases: Biosynex

News in other languages: Biosynex

Quotes and Performance

Course Extremes

Managers and Directors: Biosynex

Latest insider transactions

Diagnostic & Testing Substances

Financials

Company Profile

Quotes

Income Statement and Estimates

06-13	Agenda des dividendes et des AG France : GTT, Alten et Exail sur les tablettes
06-11	Bourse : J-1 avant SpaceX, Oracle à la peine, contrat pour Airbus
06-11	Une bonne grosse purge avant SpaceX
06-11	Triple actualité pour Biosynex
06-11	BIOSYNEX SA: BIOSYNEX ANNONCE LA REALISATION DEFINITIVE DE LA CESSION DE SON ACTIVITE DE BIOLOGIE MOLECULAIRE

1 day	-0.66%
1 week	+1.12%
Current month	+0.22%
1 month	-6.80%
3 months	+17.40%
6 months	+56.40%
Current year	+51.68%

1 week	0.89	0.93
1 month	0.88	1.07
Current year	0.56	1.57
1 year	0.46	1.57
3 years	0.46	11
5 years	0.46	28.78
10 years	0.46	30.38

Manager	Title	Age	Since
Larry Abensur CEO	Chief Executive Officer	71	2015-06-23
Thierry Paper CTO	Chief Tech/Sci/R&D Officer	63	2014-12-31
Oren Bitton PRN	Corporate Officer/Principal	-	-

Director	Title	Age	Since
Thierry Paper BRD	Director/Board Member	63	2015-06-23
Thomas Lamy BRD	Director/Board Member	-	2015-06-23
Larry Abensur CHM	Chairman	71	2015-06-23

Date	Insider	Type	Main position	Quantity	% Market Cap.
23-02-14	Elie Fraenckel	Buy	Director	2,500	0.0244%
23-02-14	Elie Fraenckel	Buy	Director	2,500	0.0244%
22-02-27	Larry Abensur	Buy	Chief Executive Officer	2,500	0.0225%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOSYNEX	-0.66%	+1.12%	-27.68%	-90.57%	19.1M
GUARDANT HEALTH, INC.	-1.63%	+17.52%	+234.75%	+369.22%	22.64B
BIOMÉRIEUX	+0.71%	+0.71%	-40.37%	-26.55%	9.42B
LANTHEUS HOLDINGS, INC.	+0.85%	+0.81%	+38.02%	+30.95%	7.09B
CARIS LIFE SCIENCES, INC.	-2.40%	-2.14%	-31.51%	-	5.3B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	+0.89%	+3.80%	-20.22%	-25.08%	5.07B
10X GENOMICS, INC.	-0.10%	+9.18%	+199.85%	-30.14%	4.96B
ANDON HEALTH CO., LTD.	-3.39%	-6.50%	+84.25%	+90.74%	4.28B
DIASORIN S.P.A.	0.00%	+4.49%	-24.01%	-27.27%	4.21B
AUTOBIO DIAGNOSTICS CO., LTD.	+0.84%	+1.86%	-19.47%	-41.72%	2.51B
Average	-0.49%	+4.60%	+39.36%	+27.73%	6.55B
Weighted average by Cap.	-0.69%	+7.95%	+93.68%	+136.54%

	2024	2025
Net sales	101M 116M 92.9M 86.63M 164M 11.02B 167M 1.12B 433M 5.41B 435M 425M 18.63B	95.19M 109M 87.41M 81.52M 155M 10.37B 157M 1.05B 408M 5.09B 409M 400M 17.53B
Net income	-43.33M -49.59M -39.79M -37.11M -70.35M -4.72B -71.53M -479M -186M -2.32B -186M -182M -7.98B	-58.22M -66.63M -53.47M -49.86M -94.52M -6.34B -96.12M -644M -249M -3.11B -250M -245M -10.72B
Net Debt	52.94M 60.58M 48.61M 45.33M 85.94M 5.77B 87.39M 585M 227M 2.83B 227M 223M 9.75B	53.19M 60.87M 48.84M 45.55M 86.35M 5.8B 87.81M 588M 228M 2.84B 229M 224M 9.79B